Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

49.38 +0.13 (+0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 548,681
Open 48.80
Bid (Size) 49.29 (4,900)
Ask (Size) 49.38 (600)
Prev. Close 49.25
Today's Range 48.23 - 49.87
52wk Range 29.16 - 59.68
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
Supernus Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.1%. The stock now trades at $53.23, m... 
Via StockStory
Topics Stocks Supply Chain
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Posts Strong Q4 Beat as CNS Portfolio Accelerates Growth ↗
Via Chartmill

Performance

YTD
-0.2%
-0.2%
1 Month
-2.6%
-2.6%
3 Month
-4.1%
-4.1%
6 Month
+5.1%
+5.1%
1 Year
+51.0%
+51.0%

More News

Read More
News headline image
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales
Via StockStory
News headline image
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Participate in March Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Topics Artificial Intelligence
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Via Investor Brand Network
Topics Intellectual Property
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
From BioMedWire
Via GlobeNewswire
News headline image
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
Via StockStory
Topics Stocks Supply Chain
News headline image
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Cash-Heavy Stock on Our Buy List and 2 We Brush Off
Via StockStory
News headline image
1 Healthcare Stock to Consider Right Now and 2 We Brush Off
Via StockStory
Topics Stocks
News headline image
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds
Via StockStory
News headline image
3 Unprofitable Stocks We Steer Clear Of
Via StockStory
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
News headline image
Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
Via MarketMinute
News headline image
3 Low-Volatility Stocks We’re Skeptical Of
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks That Concern Us
Via StockStory
News headline image
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗
Via Stocktwits
Topics Cannabis ETFs Government
News headline image
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Cash-Heavy Stock for Long-Term Investors and 2 We Turn Down
Via StockStory
News headline image
3 Stocks Under $50 That Concern Us
Via StockStory
News headline image
3 Unprofitable Stocks We Find Risky
Via StockStory
News headline image
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds
Via StockStory
Topics Stocks

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 49.38
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 03/24/26 04:00 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.62B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.